JR Rahn is co-founder, director, and Co-CEO of the psychedelic research company MindMed. He studied Chinese Language at Peking University and earned a Bachelor of Arts degree in Chinese Language and Government from Hamilton College in 2009.
Mr. Rahn, along with MindMed co-founder Stephen Hurst, is leading their drug discovery and development teams in conducting clinical trials and other research on candidate psychedelics for therapeutic use.
In an April 1, 2020 press release, MindMed announced a long-term partnership with Liechti Lab, centering around their years of research on psychedelic compounds. Under the terms of the agreement, “MindMed gains exclusive worldwide rights to data, compounds, and patent rights associated with the Liechti laboratory’s research with LSD and other psychedelic compounds, including data from preclinical studies and eight completed or ongoing LSD clinical trials.”
Part of the technology emerging from the partnership was announced by MindMed in an April 21, 2020 press release. They announced a patent filing of what they call a “neutralizer technology” that can shorten and stop a patient’s LSD trip while they are undergoing therapy.
Mr. Rahn told New Atlas, “The innovative and original work of the Liechti Laboratory is a treasure trove of novel data on LSD. We are just at the beginning of several significant discoveries that have the potential to further the application of psychedelics as therapeutic medicines. If developed, these discoveries will benefit both patients and therapists working in the psychedelic medicine space.”